Detection and Outcome of Endocervical Atypia in Cytology in Primary HPV Screening Programme.

HPV adenocarcinoma in situ atypical endocervical cells cytology endocervical adenocarcinoma screening

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
20 Dec 2021
Historique:
received: 22 11 2021
revised: 06 12 2021
accepted: 08 12 2021
entrez: 24 12 2021
pubmed: 25 12 2021
medline: 25 12 2021
Statut: epublish

Résumé

Most endocervical adenocarcinomas (EAC) are associated with high-risk HPV (hrHPV) infection, with HPV genotypes 16, 18 and 45 accounting for >90% of the cases. Among endocervical glandular lesions, screening with hrHPV test has previously shown to predict the outcome better than cytology, although around one-fifth of the EAC remain negative both in hrHPV testing and cytology. The study consists of two consecutive HPV-primary screening rounds, conducted in 2012-2015 and 2017-2020. Of the 87 women aged 35 to 60 years of age diagnosed with Atypical endocervical cells, NOS or Atypical endocervical cells, favor neoplastic cytology during the first screening round, 63 (72.4%) were hrHPV positive and 24 (27.6%) were hrHPV negative. Among hrHPV positive patients, three EAC, two adenocarcinomas in situ (AIS), one AIS + high-grade intraepithelial lesion (HSIL) and 13 HSIL were found. Of the histologically verified lesions, 68.4% (13/19) were purely of squamous origin. All the EAC and AIS were HPV16 or HPV 18 positive. No high-grade histological lesions were found among the hrHPV negative patients with cytological glandular atypia. A later database search revealed one HPV-negative, gastric-type mucinous EAC that was missed by the HPV primary screening.

Identifiants

pubmed: 34943636
pii: diagnostics11122402
doi: 10.3390/diagnostics11122402
pmc: PMC8700048
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Competitive Research Funding of the Pirkanmaa Hospital District
ID : X5211

Références

J Natl Cancer Inst. 2018 May 1;110(5):501-508
pubmed: 29145648
Diagn Cytopathol. 2016 May;44(5):389-93
pubmed: 26878832
JAMA. 2018 Jul 3;320(1):43-52
pubmed: 29971397
Acta Cytol. 2017;61(4-5):359-372
pubmed: 28693017
N Engl J Med. 2007 Oct 18;357(16):1589-97
pubmed: 17942872
Mod Pathol. 2014 Dec;27(12):1559-67
pubmed: 24762548
Cytopathology. 2009 Dec;20(6):351-8
pubmed: 18522633
Diagn Cytopathol. 2008 Apr;36(4):270-4
pubmed: 18335557
Lancet Oncol. 2010 Mar;11(3):249-57
pubmed: 20089449
Br J Cancer. 2019 May;120(10):1015-1022
pubmed: 30988395
Eur J Cancer. 2015 May;51(8):950-68
pubmed: 25817010
Diagn Cytopathol. 1995 Oct;13(3):202-8
pubmed: 8575278
Diagnostics (Basel). 2021 Mar 30;11(4):
pubmed: 33808260
Lancet Oncol. 2011 Jul;12(7):663-72
pubmed: 21684207
APMIS. 2019 Nov;127(11):710-716
pubmed: 31403733
Cancer Cytopathol. 2016 Aug;124(8):589-95
pubmed: 27115423
Int J Cancer. 2016 Jan 15;138(2):409-16
pubmed: 26334557
Am J Clin Pathol. 2002 Jan;117(1):96-102
pubmed: 11789738
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Gynecol Oncol. 2015 Feb;136(2):189-97
pubmed: 25579108
Acta Cytol. 1999 May-Jun;43(3):351-6
pubmed: 10349361
Int J Gynecol Pathol. 1993 Jul;12(3):208-18
pubmed: 8344758
Acta Obstet Gynecol Scand. 2016 Nov;95(11):1220-1227
pubmed: 27591407
Acta Obstet Gynecol Scand. 2021 Mar;100(3):403-409
pubmed: 33037625
Diagn Cytopathol. 2017 Oct;45(10):867-872
pubmed: 28771986
Cancer. 2008 Aug 25;114(4):236-41
pubmed: 18548530
Diagnostics (Basel). 2021 Aug 05;11(8):
pubmed: 34441354
Lancet Oncol. 2012 Jan;13(1):78-88
pubmed: 22177579
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Cytopathology. 2008 Feb;19(1):34-43
pubmed: 18205627
Health Technol Assess. 2009 Nov;13(51):1-150, iii-iv
pubmed: 19891902
Cytopathology. 2019 Mar;30(2):150-156
pubmed: 30421573

Auteurs

Johanna Pulkkinen (J)

Pathology, Fimlab Laboratories, Arvo Ylpön katu 4, 33520 Tampere, Finland.

Saara Kares (S)

Pathology, Fimlab Laboratories, Arvo Ylpön katu 4, 33520 Tampere, Finland.

Heini Huhtala (H)

Faculty of Social Sciences, Tampere University, Arvo Ylpön katu 34, 33520 Tampere, Finland.

Ivana Kholová (I)

Pathology, Fimlab Laboratories, Arvo Ylpön katu 4, 33520 Tampere, Finland.
Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33520 Tampere, Finland.

Classifications MeSH